

Mark Jones

Associate



majones@cooley.com

+44 (0) 20 7556 4242

London

Mergers and Acquisitions

Venture Capital

Capital Markets

Emerging Companies

Mark Jones is an associate in Cooley's corporate practice. Mark acts on a range of matters for high growth companies, investors, entrepreneurs/founders and management teams, with particular expertise on mergers and acquisitions, private equity, emerging companies/venture capital and corporate re-organisations.

Mark is recognised by The Legal 500 (UK) in its '*Corporate and commercial – M&A: lower mid-market deals (£50m-£500m)*' category.

Notable recent transactions/matters include advising:

M&A/private equity

- The management team of software company, Calypso Technology, Inc., on the sale of Calypso to Thoma Bravo, a US based private equity house, for \$3.4bn
- Kpler, a leading provider of technology-led data, analytics and market insight, on its strategic growth investment of more than \$200 million from Five Arrows and Insight Partners
- Eagle Pharmaceuticals, Inc. on its recommended acquisition, by way of a scheme of arrangement, of Acacia Pharma Group plc
- Pizza Hut Restaurants UK and its senior leadership team, led by CEO Jens Hofma, on the management buyout of the business from Rutland Partners
- Thrasio Holdings, Inc., the world's largest Amazon aggregator and fastest-ever profitable US unicorn, on several acquisitions of UK based companies
- Susquehanna Private Capital, LLC on its £70m purchase of thebigword Group, a leading provider of language translation services
- PrimaryCapital Partners on the sale of the Leisure Pass Group to Exponent Private Equity
- Blue Minerva Limited, a HG Capital backed acquisitive company, on the £40m purchase of PS Financials (Holdings) Limited and various other portfolio companies
- JourneyGroup on its \$24m scheme of arrangement and recommended offer from Jaguar Holdings

Emerging companies / venture capital

- Snyk, the world leader in developer security, on its \$530m series F round, \$300m series E round and \$200m series D round

- Orchard Therapeutics on its \$150m series C round
- Accel Partners on its £85m investment in Monzo
- Gymbox, a London-based cutting edge gym chain, on its £39m investment from BGF and HSBC
- Bit Bio, a cell coding company, on its \$41m series A round
- Manual, a wellness platform, on its \$30m series A round
- Rooser, an online seafood marketplace, on its \$23m series A round
- General Catalyst on its investment in Beauty Pie, an online beauty platform
- Several early-stage life science and technology companies on their series seed, series A, B and C rounds

Capital markets / holding company re-organisations

- Immunocore, a leading UK biotechnology company, on its \$273 million IPO and listing on Nasdaq
- Autolus Therapeutics, a leading UK biotechnology company, on its \$173 million IPO and listing on Nasdaq
- Entasis Therapeutics on its \$75m IPO and listing on Nasdaq
- F-star Therapeutics on its corporate re-organisation

During his training contract, Mark was seconded to an online retailer where he acted on a variety of matters, including the resolution of small claims, the negotiation of commercial terms and conditions and actioning 'notice and takedown' requests.

Prior to joining Cooley, Mark worked in White & Case's corporate department for a year. Mark also spent a year working in China as an English teacher.

Mark graduated from the University of Liverpool in 2011 with an LLB (Hons) Law degree. He subsequently completed the LPC in 2014, earning a Distinction.

Education

The University of Law
LPC, 2014

University of Liverpool
LLB , 2011

Rankings & Accolades

The Legal 500 UK: M&A (2022)